OM Stock Cash Flow Statements

Outset Medical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Outset Medical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31

cash flows from operating activities:
net income	-39,944,000	-38,600,000	-46,180,000	-44,046,000	-43,971,000	-41,444,000	-40,781,000	-43,839,000	-36,892,000	-41,232,000	-30,470,000	-30,208,000	-30,025,000	-32,043,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation expense	8,203,000	9,098,000	10,893,000	10,105,000	8,538,000	7,353,000	7,430,000	7,414,000	5,006,000	4,792,000	2,864,000	3,937,000	5,852,000
depreciation and amortization	1,460,000	1,446,000	1,466,000	1,514,000	1,384,000	1,269,000	1,314,000	1,324,000	1,262,000	1,296,000	1,313,000	1,307,000	1,246,000	1,930,000
non-cash lease expense	346,000	352,000	316,000	308,000	295,000	288,000	282,000	275,000	269,000	263,000	258,000	252,000	249,000	245,000
non-cash interest expense	607,000	451,000	463,000	451,000	463,000	-45,000	144,000	142,000	140,000	143,000	144,000	142,000	140,000	144,000
accretion (amortization) of discount (premium) on investments	-1,577,000	-1,270,000	-1,746,000	-1,803,000	-1,550,000
benefit from inventories	450,000	61,000	-196,000	-2,000	870,000	993,000	809,000	312,000	496,000	257,000	441,000	210,000	115,000	91,000
other non-cash items	-1,000	43,000	67,000	198,000	-18,000	50,000	-3,000	26,000	3,000
changes in operating assets and liabilities:
accounts receivable	-3,497,000	2,470,000	1,355,000	-2,695,000	-6,224,000	-5,585,000	2,115,000	2,263,000	-1,299,000	-6,299,000	-2,892,000	-4,300,000	-5,646,000	631,000
inventories	-6,981,000	-960,000	-3,507,000	3,241,000	2,873,000	2,962,000	-2,381,000	-11,127,000	-4,184,000	-4,117,000	-5,809,000	-4,869,000	-7,247,000	-7,051,000
prepaid expenses and other assets	-400,000	299,000	-756,000	627,000	569,000	-1,943,000	658,000	-67,000	137,000	1,142,000	148,000	1,551,000	-981,000	-848,000
accounts payable	945,000	3,061,000	569,000	207,000	1,475,000	-706,000	-1,259,000	-2,592,000	3,276,000	-915,000	358,000	-4,122,000	1,613,000	369,000
accrued compensation and related benefits	-4,462,000	-2,540,000	4,083,000	3,042,000	-7,100,000
accrued expenses and other current liabilities	-1,367,000	1,487,000	-388,000	-1,383,000	-2,337,000	-665,000	-5,890,000	4,140,000	4,226,000	2,393,000	1,988,000	1,344,000	164,000	-338,000
accrued warranty liability	-512,000	-356,000	-100,000	598,000	-51,000	165,000	12,000	-184,000	-76,000	470,000	161,000	213,000	-53,000	-345,000
deferred revenue	1,197,000	901,000	-16,000	1,789,000	341,000	846,000	10,000	930,000	375,000	1,331,000	433,000	812,000	305,000	-927,000
operating lease liabilities	-379,000	-385,000	-322,000	-327,000	-313,000	-306,000	-296,000	-277,000	-271,000	-265,000	-257,000	-191,000	-169,000	-164,000
net cash from operating activities	-45,912,000	-24,442,000	-33,999,000	-28,176,000	-44,756,000	-34,507,000	-34,312,000	-38,575,000	-38,335,000	-32,676,000	-28,131,000	-30,841,000	-38,616,000	-25,840,000
capex	-354,000	-1,053,000	-782,000	-795,000	-810,000	-2,109,000	-2,741,000	-1,997,000	-1,478,000	-851,000	-491,000	-847,000	-919,000	-2,662,000
free cash flows	-46,266,000	-25,495,000	-34,781,000	-28,971,000	-45,566,000	-36,616,000	-37,053,000	-40,572,000	-39,813,000	-33,527,000	-28,622,000	-31,688,000	-39,535,000	-28,502,000
cash flows from investing activities:
purchases of property and equipment	-354,000	-1,053,000	-782,000	-795,000	-810,000	-2,109,000	-2,741,000	-1,997,000	-1,478,000	-851,000	-491,000	-847,000	-919,000	-2,662,000
purchases of investment securities	-98,652,000	-51,022,000	-23,413,000	-29,702,000	-68,147,000	-92,539,000	-35,600,000	-68,303,000	-64,712,000	-30,300,000	-25,731,000
maturities of investment securities	39,975,000	75,500,000	54,000,000	57,650,000	71,600,000
net cash from investing activities	-59,031,000	23,425,000	29,805,000	27,153,000	2,643,000	-51,748,000	20,159,000	-1,316,000	-33,390,000	-16,418,000	-21,822,000	-97,460,000	-6,807,000	10,358,000
cash flows from financing activities:
proceeds from stock option exercises and espp purchases	2,086,000
proceeds from issuance of term loans, net of issuance costs	66,524,000
net cash from financing activities	68,610,000	33,229,000	4,103,000	1,043,000	5,277,000	65,600,000	2,533,000	1,042,000	3,723,000	934,000	6,187,000	150,808,000	2,218,000	-873,000
net decrease in cash, cash equivalents and restricted cash	-36,333,000	32,212,000	-91,000	20,000	-36,836,000		-11,620,000	-38,849,000	-68,002,000
cash, cash equivalents and restricted cash as of beginning of period	71,838,000	0	0	0	76,533,000	0	0	0	215,659,000	0	0	0	328,283,000	0
cash, cash equivalents and restricted cash as of end of period	35,505,000	32,212,000	-91,000	20,000	39,697,000	-20,655,000	-11,620,000	-38,849,000	147,657,000	-48,160,000	-43,766,000	22,507,000	285,078,000	-16,355,000
supplemental cash flow disclosures:
cash paid for income taxes	256,000	88,000	92,000	110,000	201,000	51,000	51,000	78,000	205,000	11,000	30,000
cash paid for interest	4,924,000	9,011,000	-3,295,000	2,652,000	2,479,000	2,141,000	423,000	339,000	282,000	288,000	709,000	-133,000	282,000	1,089,000
cash paid for amounts included in the measurement of operating lease liabilities	379,000	385,000	322,000	327,000	313,000	306,000	296,000	277,000	271,000	265,000	257,000	191,000	169,000
supplemental non-cash investing and financing activities:
capital expenditures included in accounts payable and accrued expenses	37,000		-9,000	161,000	55,000		-1,057,000	706,000	907,000				238,000
transfer of inventories to property and equipment	93,000
loss on extinguishment of term loan														0
accrued interest														0
repayment of term loan and extinguishment costs														0
proceeds from issuance of common stock upon the follow-on public offering, net of issuance costs
proceeds from stock option exercises and employee stock purchase plan purchases			4,103,000	1,043,000	5,277,000	609,000	2,668,000	1,042,000	3,723,000	934,000	6,187,000	1,723,000	2,218,000
payment of deferred financing costs
right-of-use assets obtained in exchange for operating lease liabilities			-14,000
accretion of discount on investments						-632,000	46,000	368,000	667,000		738,000	375,000	60,000
accrued payroll and related benefits						2,247,000	3,478,000	2,317,000	-11,470,000	7,190,000	2,451,000	2,706,000	-4,244,000	5,995,000
sales and maturities of investment securities						42,900,000	58,500,000	68,984,000	32,800,000	14,733,000	4,400,000
proceeds from issuance of term loan, net of issuance costs														0
proceeds from issuance of common stock upon initial and follow-on public offerings, net of issuance costs										0
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs														0
proceeds from cash exercise of redeemable convertible preferred stock warrants														0
net increase in cash, cash equivalents and restricted cash										-48,160,000	-43,766,000	22,507,000	-43,205,000	-16,355,000
proceeds from issuance of common stock upon follow-on public offerings, net of issuance costs
transfer of property and equipment to inventories
benefit from accounts receivable										0	0	0	5,000	-17,000
loss on disposal of property and equipment														230,000
change in fair value of redeemable convertible preferred stock warrant liability														0
repayment of finance lease														-1,000
proceeds from exercise of common stock warrant
payment of redeemable convertible preferred stock issuance costs
proceeds from issuance of common stock upon follow-on public offering, net of issuance costs
payment of deferred offering costs
purchases of short-term investments													-25,788,000	0
sales and maturities of short-term investments													19,900,000	12,989,000
deemed dividend on settlement of accrued dividend
adjustment to redemption value on redeemable convertible preferred stock
issuance of common stock on settlement of accrued dividend
amortization (accretion) of premium (discount) on investments														-10,000
proceed from sales of property and equipment
proceeds from issuance of common stock upon initial public offering, net of issuance costs paid														-923,000
proceeds from stock option exercises														51,000
stock-based compensation

We provide you with 20 years of cash flow statements for Outset Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Outset Medical stock. Explore the full financial landscape of Outset Medical stock with our expertly curated income statements.

The information provided in this report about Outset Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.